PMID- 33710764
OWN - NLM
STAT- MEDLINE
DCOM- 20211207
LR  - 20211214
IS  - 1759-7714 (Electronic)
IS  - 1759-7706 (Print)
IS  - 1759-7706 (Linking)
VI  - 12
IP  - 9
DP  - 2021 May
TI  - A retrospective analysis of pembrolizumab plus chemotherapy versus pembrolizumab 
      monotherapy for advanced or recurrent non-small cell lung cancer.
PG  - 1387-1397
LID - 10.1111/1759-7714.13915 [doi]
AB  - BACKGROUND: Although clinical trials have investigated the addition of 
      pembrolizumab to chemotherapy for non-small cell lung cancer, none have 
      investigated the addition of chemotherapy to pembrolizumab. METHODS: We conducted 
      a retrospective study of 71 NSCLC patients including 33 treated with 
      pembrolizumab plus chemotherapy (combination therapy group) and 38 treated with 
      pembrolizumab monotherapy (monotherapy group) from 1 May 2016 to 31 August 2020. 
      RESULTS: Eleven of 33 (33.3%) patients in the combination therapy group and 37 of 
      38 (97.4%) patients in the monotherapy group had programmed cell death ligand-1 
      (PD-L1) tumor proportion score (TPS) >/=50%. Objective response rate (ORR) and 
      median overall survival (OS) were not significantly different between the 
      combination therapy group and monotherapy group (54.5% vs. 47.4, p = 0.637 and 
      16.6 vs. 27.0 months, p = 0.463). In patients with PD-L1 TPS >/=50%, ORR and median 
      OS were not different between the combination therapy group and the monotherapy 
      group (63.6% vs. 48.6%, p = 0.499 and not reached vs. 27.0 months, p = 0.976). 
      Thirty-three (100%) patients experienced adverse events (AEs) in the combination 
      therapy group and 32 (84.2%) in the monotherapy group. Treatment discontinuation 
      at 1 year due to AEs occurred more frequently in the combination therapy group 
      (45.2%) than in the monotherapy group (21.1%). CONCLUSION: There was no 
      significant difference in ORR and OS between the two groups, and treatment 
      discontinuation was more frequent in the combination group. A randomized 
      controlled trial is needed to evaluate the addition of chemotherapy to 
      pembrolizumab for first-line treatment in patients with PD-L1 TPS >/=50%.
CI  - (c) 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and 
      John Wiley & Sons Australia, Ltd.
FAU - Isono, Taisuke
AU  - Isono T
AUID- ORCID: 0000-0002-2803-8049
AD  - Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory 
      Center, Saitama, Japan.
FAU - Kagiyama, Naho
AU  - Kagiyama N
AD  - Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory 
      Center, Saitama, Japan.
FAU - Shibata, Shun
AU  - Shibata S
AD  - Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory 
      Center, Saitama, Japan.
FAU - Nakajima, Hitomi
AU  - Nakajima H
AD  - Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory 
      Center, Saitama, Japan.
FAU - Matsui, Yuma
AU  - Matsui Y
AD  - Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory 
      Center, Saitama, Japan.
FAU - Takano, Kenji
AU  - Takano K
AD  - Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory 
      Center, Saitama, Japan.
FAU - Nishida, Takashi
AU  - Nishida T
AD  - Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory 
      Center, Saitama, Japan.
FAU - Hosoda, Chiaki
AU  - Hosoda C
AD  - Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory 
      Center, Saitama, Japan.
FAU - Kawate, Eriko
AU  - Kawate E
AD  - Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory 
      Center, Saitama, Japan.
FAU - Kobayashi, Yoichi
AU  - Kobayashi Y
AD  - Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory 
      Center, Saitama, Japan.
FAU - Ishiguro, Takashi
AU  - Ishiguro T
AD  - Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory 
      Center, Saitama, Japan.
FAU - Takaku, Yotaro
AU  - Takaku Y
AD  - Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory 
      Center, Saitama, Japan.
FAU - Kurashima, Kazuyoshi
AU  - Kurashima K
AD  - Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory 
      Center, Saitama, Japan.
FAU - Yanagisawa, Tsutomu
AU  - Yanagisawa T
AD  - Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory 
      Center, Saitama, Japan.
FAU - Takayanagi, Noboru
AU  - Takayanagi N
AD  - Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory 
      Center, Saitama, Japan.
LA  - eng
PT  - Journal Article
DEP - 20210312
PL  - Singapore
TA  - Thorac Cancer
JT  - Thoracic cancer
JID - 101531441
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - DPT0O3T46P (pembrolizumab)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antibodies, Monoclonal, Humanized/pharmacology/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/mortality/pathology
MH  - Drug Therapy/*methods
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/mortality/pathology
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Survival Analysis
PMC - PMC8088931
OTO - NOTNLM
OT  - adverse event
OT  - combination therapy
OT  - immune checkpoint inhibitor
OT  - overall survival
OT  - treatment discontinuation
EDAT- 2021/03/13 06:00
MHDA- 2021/12/15 06:00
PMCR- 2021/05/01
CRDT- 2021/03/12 13:02
PHST- 2021/02/15 00:00 [revised]
PHST- 2021/01/05 00:00 [received]
PHST- 2021/02/15 00:00 [accepted]
PHST- 2021/03/13 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2021/03/12 13:02 [entrez]
PHST- 2021/05/01 00:00 [pmc-release]
AID - TCA13915 [pii]
AID - 10.1111/1759-7714.13915 [doi]
PST - ppublish
SO  - Thorac Cancer. 2021 May;12(9):1387-1397. doi: 10.1111/1759-7714.13915. Epub 2021 
      Mar 12.